Tecvayli

News

J&J's Tecvayli claims third national priority FDA approval

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

J&J says 2026 sales could top $100 billion

J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.

News

J&J builds case for earlier Tecvayli use in multiple myeloma

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

J&J says two drugs are better than one in pretreated myeloma

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.

News

NICE updates on controversial multiple myeloma decisions

NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.

J&J's Tecvayli claims third national priority FDA approval

J&J says 2026 sales could top $100 billion

J&J builds case for earlier Tecvayli use in multiple myeloma

J&J claims FDA's latest national priority voucher

J&J says two drugs are better than one in pretreated myeloma

NICE updates on controversial multiple myeloma decisions

Reports: Makary out, Diamantas in as FDA commissioner

Discover a new era of healthcare panel engagement: Grounded ...

Tecvayli

Editor's Picks